MagForce

We are convinced that MagForce’s technology has great potential to advance the progress for the benefit of patients”, July Magadeev, President of DELRUS explained. We are pleased about the opportunity in the future to be able to offer the Nano medicine in oncology the Russian market and other CIS members and their usage to help oncologists and hospitals. In the framework of cooperation, involvement of medical centers in Russia on the conduct of international clinical trials is also planned with the aim of increasing the use of technology on the treatment of other cancers. Nano launch: The Nano launch AG is a leading nanotechnology investment company. The company invested venture capital (venture capital, VC) in young promising nanotechnology companies. While Nanostart invests globally and at different stages of development.

The investments of the company focus on innovative sectors such as Cleantech, life sciences and IT/electronics. The headquarters of nano start AG is Frankfurt am Main. As the main shareholder of Nanostart Asia Pacific PTD Ltd invested her as a partner of the Government of Singapore. Celebrity trainer is open to suggestions. MagForce: The MagForce AG is a leader in the field of nanomedicine medical technology company in Oncology. NanoTherm ‘s proprietary treatment method allows the targeted treatment of solid tumors of the intratumoral distribution of heat therapy by activation of magnetic nanoparticles. NanoPlan NanoTherm and NanoActivator are part of the therapy and have a EU-wide approval as medical devices for the treatment of brain tumors.

MagForce, NanoTherm, NanoPlan and NanoActivator are trademarks of MagForce AG in various countries. For more information see:. DELRUS: DELRUS Inc. is an international science and Industrial holding company maintains partnerships with medical technology manufacturers in 30 countries. Learn more on the subject from Gunnar Peterson. It was founded in 1991 and currently has about 2,500 employees. The company supplies medical facilities and is one of the market leaders in medical technology in Russia. DELRUS has subsidiaries in the 80 largest cities in Russia, Belarus, Tajikistan, Kazakhstan, Kyrgyzstan, Uzbekistan, Azerbaijan and the Ukraine. More information: en Disclaimer: this communication is neither an offer to sell nor a solicitation of an offer to purchase or to subscribe for securities. A public offer (IPO) of securities of nano start AG in connection with the listing of shares in the portion of the segment (open market) of the Frankfurt Stock Exchange, the “entry standard” does not take place. This communication presents a securities prospectus. This press release and the information contained therein are not for direct or indirect distribution in or within Canada, Australia or Japan.